Peripheral Vascular Disease and Nerve Stimulation (CCLINS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01942941
Recruitment Status : Completed
First Posted : September 16, 2013
Last Update Posted : May 30, 2014
Information provided by (Responsible Party):
Daniel Carradice, University of Hull

Brief Summary:
A study to see what effect the geko™ device has on blood flow in patients with lower limb vascular disease.

Condition or disease Intervention/treatment Phase
Critical Limb Ischaemia Claudication Ulcers Varicose Veins Post Angioplasty Device: geko™ electrical stimulation Phase 4

  Show Detailed Description

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 80 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Prospective Observational Series to Establish the Haemodynamic Efficacy and Tolerability of gekoTM Device in Patients With Lower Limb Vascular Disease
Study Start Date : June 2013
Actual Primary Completion Date : May 2014
Actual Study Completion Date : May 2014

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: geko™ electrical stimulation
Applied to stimulate peroneal nerve unilaterally
Device: geko™ electrical stimulation
applied to stimulate peroneal nerve and cause active muscle twitch

Primary Outcome Measures :
  1. Effect of geko™ on blood volume flow through the femoral artery [ Time Frame: Study day i.e. 1 day ]
    Measured with ultrasound doppler

Secondary Outcome Measures :
  1. Effect of geko™ on venous blow flow [ Time Frame: Study day i.e. 1 day ]
    Measured with ultrasound doppler

  2. Effect of geko™ on microcirculatory flow [ Time Frame: Study day i.e. 1 day ]
    Measured with laser doppler

  3. Establish whether effects of geko™ are local or systemic [ Time Frame: Study day i.e. 1 day ]
    Measurements will be taken from both the leg on which the device is active and the leg with no geko™

  4. Effect of geko™ on patients symptoms [ Time Frame: study day i.e. 1 day ]
    Completion of McGill pain questionnaire and visual analogue scale

  5. Acceptability and tolerability of geko™ device [ Time Frame: study day i.e. 1 day ]
    Completion of tolerability questionnaire

  6. Effect of gekoTM on calf circumference [ Time Frame: Study day i.e. 1 day ]
    Calf circumference measured before and after device

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Age >18 years
  • Absence of haematological disorders or DVT (deep vein thrombosis) in the preceding 12 months
  • Intact cutaneous sensations to nocioception in the lower limb, as determined by the investigator
  • Intact healthy skin at site of application
  • On effective contraception if sexually active - oral contraceptive pill (> 3 months use), condoms, intrauterine contraceptive device, depot injection
  • Able to understand the Patient Information Sheet and capable and willing to give informed consent and follow the protocol requirements

Exclusion Criteria:

  • History of haematological disorder or DVT in the preceding 12 months
  • Pregnant or planning to become pregnant during study duration
  • Pacemakers or implantable defibrillators
  • Use of any other neuro-modulation device
  • Current use of TENS (transcutaneous electrical nerve stimulation) in pelvic region, back or legs
  • Use of investigational drug/device therapy within past 4 weeks that may interfere with this study.
  • Significant varicose veins or lower limb ulceration.
  • Recent surgery (such as abdominal, gynaecological, hip knee replacement).
  • Recent trauma to lower limbs.
  • Chronic Obesity (BMI Index >34).
  • Any medication judged to be significant by the Principal Investigator.
  • Any significant illness during the four (4) weeks preceding the screening period of the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01942941

United Kingdom
Hull Royal Infirmary
Hull, EastRiding of Yorkshire, United Kingdom, HU3 2JZ
Sponsors and Collaborators
University of Hull
Principal Investigator: Rachel Barnes, MRCS, MA Academic Department of Vascular Surgery, Hull Royal Infirmary/ Hull York Medical School

Responsible Party: Daniel Carradice, Principle Investigator: Rachel Barnes, University of Hull Identifier: NCT01942941     History of Changes
Other Study ID Numbers: 12/EE/0314
First Posted: September 16, 2013    Key Record Dates
Last Update Posted: May 30, 2014
Last Verified: May 2014

Additional relevant MeSH terms:
Vascular Diseases
Peripheral Vascular Diseases
Varicose Veins
Pathologic Processes
Cardiovascular Diseases